Overview of the Development and Use of Akt Inhibitors in Prostate Cancer

Deregulation of the PI3K-Akt-mTOR pathway plays a critical role in the development and progression of many cancers. In prostate cancer, evidence suggests that it is mainly driven by PTEN loss of function. For many years, the development of selective Akt inhibitors has been challenging. In recent phase II and III clinical trials, Ipatasertib and Capivasertib associated with androgen deprivation therapies showed promising outcomes in patients with metastatic castration-resistant prostate cancer and PTEN-loss. Ongoing trials are currently assessing several Akt inhibitors in prostate cancer with different combinations, at different stages of the disease.

Automated summary

Deregulation of the PI3K-Akt-mTOR pathway is crucial in the development and progression of various cancers. In prostate cancer, PTEN loss of function is believed to be the main driver. Despite the challenges in developing selective Akt inhibitors, recent phase II and III clinical trials have shown promising outcomes with Ipatasertib and Capivasertib in combination with androgen deprivation therapies for patients with metastatic castration-resistant prostate cancer and PTEN loss. Ongoing trials are currently evaluating different combinations of Akt inhibitors at different stages of prostate cancer.